Why did EVE.SW stock fall pre-market today?

EVE.SW stock fell **10.12%** pre-market amid a public **C+ (Sell)** company rating dated 2026-03-09 and rising intraday volume **11,236**. The small market cap and negative EPS **-0.12** make the name sensitive to analyst sentiment and trading flows.

What are immediate support and resistance levels for EVE.SW stock?

Immediate support sits at **CHF0.85** (day low and 50-day average) and resistance near **CHF0.99** (Bollinger upper). Use **CHF0.83** as a tactical stop-loss and consider **CHF1.46** as a longer-term Meyka AI yearly forecast target.

How does Meyka AI evaluate EVE.SW stock?

Meyka AI rates EVE.SW **68.15/100** (Grade B, HOLD). The grade factors benchmark and sector comparison, financial growth, key metrics and forecasts. This is informational only and not investment advice.

What catalysts could improve EVE.SW stock performance?

Positive clinical or licensing news, an earnings beat on or before the next announcement **2026-08-20**, or improved analyst sentiment could restore investor confidence. Watch sector movements in Healthcare and Biotechnology for correlated flows.

CH Stocks

EVE.SW EvoNext (SIX) down 10.12% pre-market 10 Mar 2026: watch CHF0.85 support

ByHuzaifa Zahoor March 10, 2026March 10, 2026

EVE.SW stock opened the pre-market on 10 Mar 2026 down 10.12% to CHF0.87, marking it among the top losers on the SIX Switzerland session. The move follows a March 9 company rating of C+ (Sell) and above-average volume of 11,236 shares versus a 50-day average of 7,661. We quickly review the drivers behind the drop, key ratios like EPS -0.12 and P/E -7.25, and what traders should watch at the CHF0.85 intraday support and CHF0.99 resistance levels.